Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Feb 14:13:848332.
doi: 10.3389/fphar.2022.848332. eCollection 2022.

Editorial: Ocular Pharmacology: Recent Breakthroughs and Unmet Needs

Claudio Bucolo  1 , Mario Damiano Toro  2   3 , Chiara M Eandi  4   5
Affiliations
Editorial

Editorial: Ocular Pharmacology: Recent Breakthroughs and Unmet Needs

Claudio Bucolo et al. Front Pharmacol. .
No abstract available

Keywords: age-related macular degeneration (AMD); cornea; diabetic retinopathy; glaucoma; ocular pharmacology; retinoblastoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Ocular Pharmacology: Recent Breakthroughs and Unmet Needs

References

    1. Amadio M., Pascale A., Cupri S., Pignatello R., Osera C., D'Agata V., et al. (2016). Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rats. Pharmacol. Res. 111, 713–720. 10.1016/j.phrs.2016.07.042 - DOI - PubMed
    1. Dugel P. U., Singh R. P., Koh A., Ogura Y., Weissgerber G., Gedif K., et al. (2021). HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology 128 (1), 89–99. 10.1016/j.ophtha.2020.06.028 - DOI - PubMed
    1. Lotery A., Sivaprasad S., O’Connell A., Harris R. A., Culliford L., Ellis L., et al. (2020). Eplerenone for Chronic Central Serous Chorioretinopathy in Patients with Active, Previously Untreated Disease for More Than 4 Months (VICI): A Randomised, Double-Blind, Placebo-Controlled Trial. Lancet 395 (10220), 294–303. 10.1016/S0140-6736(19)32981-2 - DOI - PubMed

Publication types